ReviewPharmaceutics2021
Drug Delivery by Ultrasound-Responsive Nanocarriers for Cancer Treatment.
Review in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
65 citing papers in PubMed, 131 citations in OpenAlex.
- Recent advances in interstitial fluid dynamics for diagnostic, targeted drug delivery and precision medicine applications.Drug delivery and translational research · 2026Review
- Marine-Derived Nanocarriers for Immunomodulatory Drug Delivery: a Review On Convergence of Marine Pharmacology and Nanotechnology.Applied biochemistry and biotechnology · 2026Review
- Hypothalamic wars: the last nanodelivery.Reviews in endocrine & metabolic disorders · 2026Review
- Dynamic DNA Nanomachines for Biosensing and Drug Delivery.Sensors (Basel, Switzerland) · 2026Review
- Advancements in Ultrasound Gel Pad Technologies: Enhancing Diagnostic Precision, Procedural Efficiency, and Therapeutic Applications.Gels (Basel, Switzerland) · 2026Review
- The Role of Biofunctional Polymers in Polymer-Drug Conjugates: From Passive Carriers to Therapeutically Active Platforms.Pharmaceutics · 2026Review
- Advances in the applications of stimulus-responsive nanomedicines for anti-cancer therapy.Nanomedicine (London, England) · 2026Review
- Acoustic Bioprinting: A Glimpse Into an Emerging Field.Small methods · 2026Review
- Cordyceps sinensis and Sonodynamic Therapy in Non-Small Cell Lung Cancer: Pharmacological Basis, Therapeutic Potential, and Future Directions.International journal of nanomedicine · 2026Review
- Smart Colloidal Systems as Drug Delivery and Therapeutic Modulation Platforms for Renal Cell Carcinoma.International journal of nanomedicine · 2026Review
- A Biocompatible Microdroplet Platform Incorporating MSC-Derived Exosomes for Bone Regeneration and Osteoporosis Treatment.International journal of nanomedicine · 2026Article
- External stimuli-responsive drug delivery to the posterior segment of the eye.Drug delivery · 2025Review
- The Glymphatic-Venous Axis in Brain Clearance Failure: Aquaporin-4 Dysfunction, Biomarker Imaging, and Precision Therapeutic Frontiers.International journal of molecular sciences · 2025Review
- Revolutionizing vaccination: the marvel of nanovaccination technology.Molecular biology reports · 2025Review
- Nanocarrier-Based Systems for Targeted Delivery: Current Challenges and Future Directions.MedComm · 2025Review
- The synergistic potential of ultrasound and nanomaterials for enhanced diagnosis and therapy of head and neck cancers.Nanomedicine (London, England) · 2025Review
- A Review of Silica-Based Nanoplatforms for Anticancer Cargo Delivery.International journal of molecular sciences · 2025Review
- Surfactant-Enabled Nanocarriers in Breast Cancer Therapy: Targeted Delivery and Multidrug Resistance Reversal.Pharmaceutics · 2025Review
- NIR-Responsive Microbubble Delivery Platforms for Controlled Drug Release in Cancer Therapy.Materials (Basel, Switzerland) · 2025Article
- Experimental studies on squeezing interstitial fluid via transfer of ultrasound momentum (SIF-TUM) inJournal of applied physics · 2025Article
5 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Conventional cancer chemotherapies often exhibit insufficient therapeutic outcomes and dose-limiting toxicity. Therefore, there is a need for novel therapeutics and formulations with higher efficacy, improved safety, and more favorable toxicological profiles. This has promoted the development of nanomedicines, including systems for drug delivery, but also for imaging and diagnostics. Nanoparticles loaded with drugs can be designed to overcome several biological barriers to improving efficiency and reducing toxicity. In addition, stimuli-responsive nanocarriers are able to release their payload on demand at the tumor tissue site, preventing premature drug loss. This review focuses on ultrasound-triggered drug delivery by nanocarriers as a versatile, cost-efficient, non-invasive technique for improving tissue specificity and tissue penetration, and for achieving high drug concentrations at their intended site of action. It highlights aspects relevant for ultrasound-mediated drug delivery, including ultrasound parameters and resulting biological effects. Then, concepts in ultrasound-mediated drug delivery are introduced and a comprehensive overview of several types of nanoparticles used for this purpose is given. This includes an in-depth compilation of the literature on the various in vivo ultrasound-responsive drug delivery systems. Finally, toxicological and safety considerations regarding ultrasound-mediated drug delivery with nanocarriers are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.